These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 17479959)

  • 1. Mucosal leishmaniasis and miltefosine.
    Tuon FF; Amato VS
    Clin Infect Dis; 2007 Jun; 44(11):1525-6; author reply 1526-7. PubMed ID: 17479959
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.
    Soto J; Rea J; Valderrama M; Toledo J; Valda L; Ardiles J; Berman J
    Am J Trop Med Hyg; 2009 Sep; 81(3):387-9. PubMed ID: 19706901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Bolivian mucosal leishmaniasis with miltefosine.
    Soto J; Toledo J; Valda L; Balderrama M; Rea I; Parra R; Ardiles J; Soto P; Gomez A; Molleda F; Fuentelsaz C; Anders G; Sindermann H; Engel J; Berman J
    Clin Infect Dis; 2007 Feb; 44(3):350-6. PubMed ID: 17205440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral miltefosine to treat new world cutaneous leishmaniasis.
    Soto J; Toledo JT
    Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of mucosal leishmaniasis (L. infantum) with miltefosine in a patient with Good syndrome.
    Stoeckle M; Holbro A; Arnold A; Neumayr A; Weisser M; Blum J
    Acta Trop; 2013 Oct; 128(1):168-70. PubMed ID: 23871798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Miltefosine (Impavido) for leishmaniasis.
    Med Lett Drugs Ther; 2014 Sep; 56(1451):89-90. PubMed ID: 25211304
    [No Abstract]   [Full Text] [Related]  

  • 8. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.
    Chrusciak-Talhari A; Dietze R; Chrusciak Talhari C; da Silva RM; Gadelha Yamashita EP; de Oliveira Penna G; Lima Machado PR; Talhari S
    Am J Trop Med Hyg; 2011 Feb; 84(2):255-60. PubMed ID: 21292895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
    Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
    [No Abstract]   [Full Text] [Related]  

  • 12. Miltefosine--the long-awaited therapy for visceral leishmaniasis?
    Herwaldt BL
    N Engl J Med; 1999 Dec; 341(24):1840-2. PubMed ID: 10588972
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis.
    Crone CG; Helleberg M
    J Travel Med; 2020 Feb; 27(1):. PubMed ID: 31776570
    [No Abstract]   [Full Text] [Related]  

  • 16. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
    Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
    J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment.
    Tappe D; Müller A; Stich A
    Am J Trop Med Hyg; 2010 Jan; 82(1):1-3. PubMed ID: 20064985
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
    Ventin F; Cincurá C; Machado PRL
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
    Croft SL; Engel J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
    Mosimann V; Neumayr A; Hatz C; Blum JA
    Infection; 2013 Dec; 41(6):1177-82. PubMed ID: 23835701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.